The Chemours Company (CC) Balance Sheet

Retained earnings declined from $1.8B to roughly $0.9B over the same window, which suggests the equity base has been consumed by losses rather than reinvested profits. Total assets stayed near $7.2B to $7.6B throughout, so the deterioration is driven by the liability and earnings side of the ledger. Investors should monitor whether the Q3 2026 rebound is sustained or reflects a single-period recovery.

Debt levels have stayed largely flat near $4.4B while equity shrank, so leverage ratios are driven by the equity denominator rather than new borrowing. The current debt load appears heavy relative to the volatile earnings base, which may constrain flexibility if the pigment cycle weakens further. Refinancing terms and maturity schedules warrant further investigation, as the reported data does not disclose them.

A current ratio near 1.7 indicates current assets exceed current liabilities, which is adequate on paper. Cash balances fluctuate meaningfully quarter to quarter, which suggests liquidity depends on working capital timing rather than a stable reserve. The buffer against a prolonged earnings downturn appears narrower than the headline ratio implies.

Goodwill of $46.0M is minimal, so impairment risk on the asset side appears low relative to the tangible base. The heavy fixed-plant concentration implies high operating leverage and sensitivity to utilization rates. The stable PP&E figure suggests capital is being maintained rather than materially expanded.